Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-05-22FDA Approved: SUMATRIPTAN SUCCINATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application from Sun Pharmaceutical Industries to bring a generic sumatriptan succinate product to market fo…
-
FDA approval · 2019-05-17FDA Approved: SUMATRIPTAN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Sumatriptan succinate from Aurobindo Pharma Limited.
-
FDA approval · 2019-05-17FDA Approved: SUMATRIPTAN SUCCINATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Sumatriptan Succinate from Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2019-04-16FDA Approved: SUMATRIPTAN SUCCINATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Sumatriptan Succinate from Mylan Pharmaceuticals, enabling regulatory approval for this gene…
-
FDA approval · 2019-04-15FDA Approved: EXCEDRIN MIGRAINE GELTABS — Supplemental Application (Haleon US Holdings LLC)
The FDA approved a supplemental application for Excedrin Migraine GelTabs. The product combines acetaminophen, aspirin, and caffeine in a ge…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-03-22FDA Approved: PROPRANOLOL HYDROCHLORIDE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical's supplemental application for propranolol hydrochloride (generic propranolol HCl).
-
FDA approval · 2019-03-11FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for AIMOVIG (erenumab-aooe) from Amgen, updating the product labeling accordingly.
-
FDA approval · 2019-02-21FDA Approved: TROKENDI XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for TROKENDI XR (topiramate) from Supernus Pharmaceuticals, authorizing an update to the product via…
-
FDA approval · 2019-01-25FDA Approved: TOSYMRA — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Tosymra, a nasal spray formulation of sumatriptan from Upsher-Smith, via an original NDA for the acute treatment of migraine wi…
-
FDA approval · 2019-01-15FDA Approved: ELETRIPTAN HYDROBROMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original abbreviated new drug application for Eletriptan hydrobromide (generic) from Aurobindo Pharma Limited. The approval…
-
FDA approval · 2018-12-28FDA Approved: BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE — Supplemental Application (LGM PHARMA SOLUTIONS, LLC)
The FDA approved a supplemental application for the generic combination product butalbital, acetaminophen, and caffeine from LGM PHARMA SOLU…
-
FDA approval · 2018-12-27FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TOPAMAX (topiramate) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2018-12-21FDA Approved: ZOMIG — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for ZOMIG (zolmitriptan) from Amneal Pharmaceuticals LLC.
-
FDA approval · 2018-11-06FDA Approved: FROVATRIPTAN — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's original generic application for frovatriptan succinate tablets used to treat acute migraine in…
-
FDA approval · 2018-10-31FDA Approved: BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE — Original Application (LGM PHARMA SOLUTIONS, LLC)
FDA approved a generic version of the combination analgesic butalbital, acetaminophen, and caffeine for headache indications.
-
FDA approval · 2018-09-27FDA Approved: EMGALITY — Original Application (Eli Lilly and Company)
The FDA approved EMGALITY (galcanezumab) under the original application filed by Eli Lilly and Company.
-
FDA approval · 2018-09-26FDA Approved: BUTALBITAL, ACETAMINOPHEN AND CAFFEINE — Original Application (Aurolife Pharma, LLC)
FDA approved a generic tablet containing butalbital, acetaminophen, and caffeine under ANDA204733 (Original Application) for Aurolife Pharma…
-
EMA approval · 2018-09-21New medicine for the prevention of migraine
The EMA announces a new medicine for the prevention of migraine, representing a new option for preventive treatment pending regulatory appro…
-
FDA approval · 2018-09-18FDA Approved: BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE PHOSPHATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for the analgesic combination Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate from Actavi…
-
FDA approval · 2018-09-14FDA Approved: AJOVY — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Ajovy (fremanezumab) from Teva as an original biologics license application for the preventive treatment of migraine in adults.
-
FDA approval · 2018-07-20FDA Approved: SUMATRIPTAN AND NAPROXEN SODIUM — Original Application (NorthStar RxLLC)
The FDA approved a generic fixed-dose combination of sumatriptan and naproxen sodium for the acute treatment of migraine, under an original …
-
FDA approval · 2018-07-17FDA Approved: IMITREX — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for IMITREX (sumatriptan) submitted by GlaxoSmithKline LLC.
-
FDA approval · 2018-06-26FDA Approved: SUMATRIPTAN — Supplemental Application (Lannett Company, Inc.)
FDA approves a supplemental application for Sumatriptan (generic) filed by Lannett Company, Inc., expanding the availability of this migrain…
-
FDA approval · 2018-06-19FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Topamax (topiramate) submitted by Janssen Pharmaceuticals, Inc.
-
EMA approval · 2018-06-01First monoclonal antibody therapy for prevention of migraine
EMA announces the approval of the first monoclonal antibody therapy for prevention of migraine.